MDS could benefit from the different therapeutic approaches that are explored for other cancers, including the stabilization of wild-type TP53, degradation of TP53 mutant, restoration of wild-type TP53 from mutant TP53, and addition of wild-type TP53 (Figure 3). This evidence concerns the gene TP53 and myelodysplastic syndrome.